SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

IRD

Opus Genetics Inc.
NASDAQHealth Care

Latest close: 3.84 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Oct 15, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  2. Sep 30, 2026Reported sale · Form 4Foundation Fighting Blindness Retinal Degeneration Fund · $2.8MOpen the filing ↗
  3. Sep 11, 2026Material event · 8-KFiled by the company itself.Open the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record95123 flagged findings
Reported transactions (Form 4)80since Jun 6, 2023 · and 8 other holdings
Corporate events (8-K)30since Jun 7, 2021

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

Identity

Formerly traded as OCUP.

SEC topics

Regulatory history

Topics detected in its SEC reports, with the original excerpt.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

  • 2026-06-17listing compliance noticerecentOpen filing ↗
    “…not be able to successfully implement our business strategy; • as we grow, we may not be able to operate internationally or…”
    +1 more passage from the same document
    • “…to operate internationally or adequately develop and expand our sales, marketing, distribution, and other corporate functions,…”
  • 2026-06-05listing compliance noticerecentOpen filing ↗
    “…not be able to successfully implement our business strategy; • as we grow, we may not be able to operate internationally or…”
    +1 more passage from the same document
    • “…to operate internationally or adequately develop and expand our sales, marketing, distribution, and other corporate functions,…”
  • 2026-05-12share offering or dilution eventrecentOpen filing ↗
    “…exercised the Pre-Funded Warrants immediately prior to such fundamental transaction. The Pre-Funded Warrants were recorded in the…”
    +1 more passage from the same document
    • “…transaction, as defined in the Form of Pre-Funded Warrant, the holders of the Pre-Funded Warrants will be entitled to receive upon…”
  • 2026-05-12listing compliance noticerecentOpen filing ↗
    “…not be able to successfully implement our business strategy; • As we grow, we may not be able to operate internationally or…”
    +1 more passage from the same document
    • “…As we grow, we may not be able to operate internationally or adequately develop and expand our sales, marketing, distribution, and…”
  • 2026-05-12capital return (buybacks/dividends)recentOpen filing ↗
    “…31, 2025 — $ — — $ — 69,894,507 $ 7 $ 203,930 $ ( 188,589 ) $ 15,348 Issuance of Series B preferred stock, net of issuance costs of…”
    +1 more passage from the same document
    • “…— $ — — $ — 69,894,507 $ 7 $ 203,930 $ ( 188,589 ) $ 15,348 Issuance of Series B preferred stock, net of issuance costs of $ 264 —…”

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 951)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Oct 15, 268-K ↗Current report · Communication to the market new
  • Insider transaction · 2 Form 4 filingsshow all 2hide
  • Sep 11, 268-K ↗Current report · Communication to the market
  • Sep 9, 268-K ↗Current report · Communication to the market · Other events
  • Insider transaction · 2 Form 4 filingsshow all 2hide
  • Sep 3, 26Form 144 ↗Notice of proposed sale
  • Aug 14, 26SCHEDULE 13G/A ↗Passive stake · Caligan Partners LP · 7.3% · event on Jun 30, 26 · amendment
  • Aug 14, 26SCHEDULE 13G/A ↗Passive stake · Perceptive Advisors LLC · 10.0% · event on Jun 30, 26 · amendment
  • Aug 14, 26SCHEDULE 13G/A ↗Passive stake · BALYASNY ASSET MANAGEMENT L.P. · 6.6% · event on Jun 30, 26 · amendment
  • Aug 13, 26CORRESP ↗Correspondence with the SEC
  • Aug 12, 26UPLOAD ↗Correspondence with the SEC
  • Aug 7, 26S-3 ↗Securities offering
  • Aug 6, 2610-Q ↗Quarterly report
  • Aug 6, 268-K ↗Current report · Results
  • Insider transaction · 4 Form 4 filingsshow all 4hide
  • Notice of proposed sale · 4 Form 144 filingsshow all 4hide
  • Jun 16, 268-K ↗Current report · Communication to the market

951 filings on record, the oldest from Aug 18, 04.

Listing the 25 most recent filings of the 951 on record.

8-Ks, explained

Stress4Structure89Governance48
  • Apr 24, 26StructureTook on a new financial obligation8-K 2.03 ↗
  • Apr 7, 26GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Apr 7, 26StructureSold unregistered shares+3 more in the same filing8-K 3.02 ↗
  • Feb 19, 26StructureSold unregistered shares+5 more in the same filing8-K 3.02 ↗
  • Nov 6, 25StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Sep 2, 25GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Aug 25, 25StructureSold unregistered shares8-K 3.02 ↗
  • Jul 23, 25StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Jun 25, 25GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Jun 20, 25StructureEntered a material agreement8-K 1.01 ↗
  • Apr 4, 25StructureA material agreement was terminated8-K 1.02 ↗
  • Mar 24, 25StructureSold unregistered shares+2 more in the same filing8-K 3.02 ↗

13 older filings not shown · The record reaches back to Jan 18, 05.

Notable in the record

Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.

  • May 29, 19StressListing notice (8-K 3.01)+2 more in the same filing8-K 3.01 ↗
  • Mar 16, 11StressPast accounts declared unreliable and being restated8-K 4.02 ↗
  • May 5, 09StressListing notice (8-K 3.01)+1 more in the same filing8-K 3.01 ↗
  • Feb 27, 09StressListing notice (8-K 3.01)+1 more in the same filing8-K 3.01 ↗

The full record holds 4 stress filings.

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13D: stake and stated purpose

Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.

  • Foundation Fighting Blindness Retinal Degeneration Fund4.7%May 18, 26SCHEDULE 13D/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • Perceptive Advisors LLC10.0%Jun 30, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
  • Adage Capital Management, L.P.8.5%Mar 31, 26SCHEDULE 13G ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
  • Caligan Partners LP7.3%Jun 30, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • BALYASNY ASSET MANAGEMENT L.P.6.6%Jun 30, 26SCHEDULE 13G/A ↗5 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
  • Nantahala Capital Management, LLC6.5%Mar 31, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 3 earlier filings
show 2 more holdershide
  • BIOS EQUITY PARTNERS III, LP6.2%May 5, 25SCHEDULE 13G ↗10 co-filers on this document — the figure is the largest single stake, not their sum.
  • AARON G.L. FLETCHER4.5%May 12, 26SCHEDULE 13G/A ↗10 co-filers on this document — the figure is the largest single stake, not their sum.

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

Sale intention announced

On Sep 3, Gagnon Robert E. filed notice of intent to sell up to $125K. That is about 0.03% of shares outstanding. It is filed under a scheduled plan (10b5-1), arranged in advance.

A notice is not a sale: it may not go ahead, may happen in part, or at a different price.

After the notice, they sold $127K on Sep 3, per their Form 4. That is 100% of the shares announced so far, and the window is still open.

View notice (Form 144) ↗+4 more recent notices · 4 with a later sale

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Sep 30, 26Sell$2.8MFoundation Fighting Blindness Retinal Degeneration Fund↗
  • Sep 3, 26Sell$127KRobert E. GagnonChief Financial Officer↗
  • Jul 23, 26Sell$23KRobert E. GagnonChief Financial Officer↗
  • Jul 23, 26Sell$28KGeorge MagrathChief Executive Officer↗
  • Jul 23, 26Sell$14KJOSEPH K SCHACHLEChief Operating Officer↗
  • Jul 23, 26Sell$22KBENJAMIN R YERXAPresident↗
  • May 18, 26Sell$7.4MFoundation Fighting Blindness Retinal Degeneration Fund↗
  • Apr 23, 26Sell$41KRobert E. GagnonChief Financial Officer↗
  • Apr 23, 26Sell$39KAshwath JayagopalChief Scientific & Dev. Ofc.↗
  • Apr 23, 26Sell$50KGeorge MagrathChief Executive Officer↗
  • Apr 23, 26Sell$9KRabourn Amy ZarembaHead of Fin. Quality Assurance↗
  • Apr 23, 26Sell$25KJOSEPH K SCHACHLEChief Operating Officer↗

There are 5 more transactions in this stretch.

Stock compensation, tax and giftsshow the 23 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Sep 9, 26Compensation$451KGeorge MagrathChief Executive Officer↗
  • Sep 9, 26Tax$451KGeorge MagrathChief Executive Officer↗
  • Sep 8, 26Compensation$902KCam Gallagher↗
  • Apr 20, 26Compensationamount n/aSean Ainsworth↗
  • Apr 20, 26Compensationamount n/aJean Bennett↗
  • Apr 20, 26Compensationamount n/aSusan Benton↗
  • Apr 20, 26Compensationamount n/aCam Gallagher↗
  • Apr 20, 26Compensationamount n/aAdrienne L Graves↗
  • Apr 20, 26Compensationamount n/aJAMES S J MANUSO↗
  • Apr 20, 26Compensationamount n/aRichard J Rodgers↗
  • Feb 12, 26Tax$18KAshwath JayagopalChief Scientific & Dev. Ofc.↗
  • Jan 22, 26Compensationamount n/aRobert E. GagnonChief Financial Officer↗
  • Jan 22, 26Compensationamount n/aAshwath JayagopalChief Scientific & Dev. Ofc.↗
  • Jan 22, 26Compensationamount n/aGeorge MagrathChief Executive Officer↗
  • Jan 22, 26Compensationamount n/aRabourn Amy ZarembaHead of Fin. Quality Assurance↗
  • Jan 22, 26Compensationamount n/aJOSEPH K SCHACHLEChief Operating Officer↗
  • Jan 22, 26Compensationamount n/aBENJAMIN R YERXAPresident↗
  • Jan 18, 26Tax$7KRabourn Amy ZarembaHead of Fin. Quality Assurance↗
  • Jan 10, 26Tax$8KRabourn Amy ZarembaHead of Fin. Quality Assurance↗
  • Jan 6, 26Compensationamount n/aCam Gallagher↗
  • Jan 1, 26Compensationamount n/aSean Ainsworth↗
  • Jan 1, 26Compensationamount n/aJean Bennett↗
  • Jan 1, 26Compensationamount n/aAdrienne L Graves↗

The full record holds 129 transactions and goes back to Dec 23, 22.

Its sector and its market

Opus Genetics Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From Opus Genetics Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow Opus Genetics Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
250 clean closes in the period.
SEC records
951 documents on file, from Aug 18, 2004 to Oct 15, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.